Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
  • Pipeline
    • Overview
    • HS-110
    • HS-130
    • Expanded Access
    • Scientific Publications
  • Investors
  • News & Media
  • Careers
  • Contact

News Releases

Heat Biologics Commences Manufacturing Process for ZVX-60

Jan 19, 2021

Heat Biologics Promotes William L. Ostrander to Chief Financial Officer

Jan 11, 2021

Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Jan 8, 2021

Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19

Dec 16, 2020

Heat Biologics Provides Business Update

Dec 10, 2020

Heat Biologics Provides Third Quarter 2020 Business Update

Nov 9, 2020

Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

Oct 7, 2020

Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Sep 9, 2020

Heat Biologics Issued Key Patent on Combination Platform Therapy

Sep 2, 2020

Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results

Aug 26, 2020
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...29
    NightHawk Biosciences

    OUR ECOSYSTEM

    SkunkWorx Bio
    Heat Biologics
    Elusys Therapeutics Inc.
    Pelican Therapeutics
    Scorpion Biological Services
    © 2022 Heat Biologics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap LinkedIn